Andreas Engert Selected Research

Panobinostat

1/2017	Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation.
5/2014	Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant.
1/2013	The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.
6/2012	Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andreas Engert Research Topics

Disease

157	Hodgkin Disease (Hodgkin's Disease) 10/2023 - 01/2002
77	Neoplasms (Cancer) 10/2023 - 01/2002
37	Lymphoma (Lymphomas) 06/2022 - 01/2002
18	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021 - 06/2002
16	Infections 08/2022 - 01/2002
9	Anemia 01/2016 - 01/2005
7	Febrile Neutropenia 12/2015 - 08/2003
7	Multiple Myeloma 10/2015 - 03/2006
6	Residual Neoplasm 10/2021 - 07/2005
6	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 02/2009 - 11/2002
5	Neutropenia 10/2018 - 08/2003
5	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2017 - 03/2006
5	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 10/2016 - 11/2003
4	Fever (Fevers) 01/2021 - 11/2002
4	Disease Progression 10/2018 - 12/2010
4	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2017 - 03/2014
4	Pathologic Complete Response 12/2011 - 03/2006
3	Hematologic Neoplasms (Hematological Malignancy) 02/2019 - 07/2012
3	Breast Neoplasms (Breast Cancer) 12/2015 - 04/2003
3	Carcinoma (Carcinomatosis) 06/2014 - 04/2003
3	Infertility (Sterility) 01/2008 - 07/2005
2	Obesity 01/2023 - 01/2019
2	Second Primary Neoplasms (Neoplasms, Second) 01/2020 - 01/2017
2	Sclerosis 12/2017 - 06/2007
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2017 - 03/2014
2	Long Term Adverse Effects 01/2017 - 02/2011
2	Fatigue 10/2016 - 05/2010
2	Thrombocytopenia (Thrombopenia) 12/2015 - 11/2002
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2015 - 05/2006
2	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 06/2009 - 09/2004
2	B-Cell Lymphoma (Lymphoma, B Cell) 06/2008 - 06/2004

Drug/Important Bio-Agent (IBA)

33	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2023 - 01/2002
27	Bleomycin (Blenoxane)FDA LinkGeneric 11/2021 - 01/2002
25	Cyclophosphamide (Cytoxan)FDA LinkGeneric 06/2021 - 01/2002
24	Prednisone (Sone)FDA LinkGeneric 06/2021 - 01/2002
23	Vincristine (Oncovin)FDA LinkGeneric 06/2021 - 01/2002
20	Procarbazine (Matulane)FDA Link 06/2021 - 01/2002
19	Etoposide (VP 16)FDA LinkGeneric 06/2021 - 01/2002
17	Rituximab (Mabthera)FDA Link 01/2020 - 11/2002
16	Brentuximab VedotinIBA 01/2022 - 06/2012
15	Vinblastine (Vinblastine Sulfate)FDA Link 01/2023 - 01/2002
15	Dacarbazine (DIC)FDA LinkGeneric 01/2023 - 01/2002
15	Monoclonal AntibodiesIBA 12/2018 - 01/2003
11	NivolumabIBA 10/2023 - 09/2016
11	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 02/2016 - 08/2003
9	AntibodiesIBA 01/2022 - 04/2003
8	LigandsIBA 12/2018 - 03/2006
7	Methotrexate (Mexate)FDA LinkGeneric 12/2020 - 01/2002
6	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2006
6	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 05/2006
6	Erythropoietin FDA Link 12/2012 - 01/2005
5	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2016
5	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 12/2005
5	AntigensIBA 01/2022 - 04/2003
5	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 02/2016 - 08/2003
4	PanobinostatIBA 01/2017 - 06/2012
4	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 02/2016 - 01/2009
4	HematinicsIBA 02/2016 - 12/2008
4	Alemtuzumab (Campath)FDA Link 02/2012 - 10/2005
4	Gemcitabine FDA Link 12/2011 - 06/2004
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2023 - 06/2004
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 04/2009
3	Cytarabine (Cytosar-U)FDA LinkGeneric 12/2020 - 02/2010
3	Immunoconjugates (Immunoconjugate)IBA 12/2017 - 07/2014
3	CytokinesIBA 12/2014 - 01/2013
3	pixantrone (BBR 2778)IBA 04/2011 - 08/2003
3	Antineoplastic Agents (Antineoplastics)IBA 07/2009 - 01/2005
3	fludarabineIBA 01/2009 - 11/2002
3	Hemoglobins (Hemoglobin)IBA 04/2005 - 01/2005
2	ORALIT (ORS)IBA 01/2023 - 10/2019
2	AFM13IBA 01/2022 - 06/2015
2	Cell-Free Nucleic AcidsIBA 10/2021 - 09/2017
2	Vitamin D FDA LinkGeneric 12/2019 - 11/2017
2	EnzymesIBA 02/2019 - 04/2003
2	Histone Deacetylase InhibitorsIBA 02/2019 - 01/2013
2	Lenalidomide (CC 5013)FDA Link 01/2019 - 02/2010
2	Lipase (Acid Lipase)FDA Link 10/2018 - 09/2016
2	pembrolizumabIBA 01/2017 - 01/2017
2	ChemokinesIBA 05/2014 - 06/2009
2	Cetuximab (Erbitux)FDA Link 03/2014 - 03/2010
2	Natural Killer Cell ReceptorsIBA 04/2013 - 08/2009
2	Interleukin-10 (Interleukin 10)IBA 01/2013 - 11/2008
2	Epoetin Alfa (Epogen)FDA Link 05/2010 - 05/2006
2	NF-kappa B (NF-kB)IBA 08/2009 - 09/2005
2	PlasticsIBA 05/2008 - 04/2003

Therapy/Procedure

80	Drug Therapy (Chemotherapy) 08/2022 - 01/2002
51	Radiotherapy 10/2023 - 01/2002
44	Therapeutics 01/2023 - 01/2002
19	Stem Cell Transplantation 09/2016 - 12/2005
14	Immunotherapy 01/2017 - 03/2002
7	Erythrocyte Transfusion 02/2016 - 01/2005
6	Aftercare (After-Treatment) 10/2021 - 01/2008
6	Combination Drug Therapy (Combination Chemotherapy) 12/2017 - 06/2004
2	Cell Transplantation 10/2023 - 10/2018
2	Combined Modality Therapy 11/2021 - 01/2002
2	Induction Chemotherapy 05/2016 - 12/2005
2	Blood Transfusion (Blood Transfusions) 02/2016 - 04/2005
2	Autologous Transplantation 10/2015 - 09/2011
2	Transplantation 10/2015 - 08/2005
2	Chemoradiotherapy 01/2009 - 07/2004